Loading clinical trials...
Loading clinical trials...
A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function
Conditions
Interventions
MTX228
DEXCOM G6
Locations
1
Canada
University of Alberta
Edmonton, Alberta, Canada
Start Date
November 14, 2024
Primary Completion Date
October 1, 2026
Completion Date
December 1, 2027
Last Updated
April 13, 2026
NCT07224321
NCT07051005
NCT02734277
NCT06575426
NCT07356089
NCT06390371
Lead Sponsor
University of Alberta
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions